Year in Review | Published:

JIA in 2011

New takes on categorization and treatment

Nature Reviews Rheumatology volume 8, pages 6768 (2012) | Download Citation

In 2011, new treatment recommendations for juvenile idiopathic arthritis (JIA) were proposed, inroads were made towards understanding the heterogeneity of this disease, and data were presented demonstrating the potential efficacy of DMARD combination therapies for JIA treatment. These advances hold promise for improved management of JIA in 2012 and beyond.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 31, 390–392 (2004).

  2. 2.

    Are the number of joints involved or the presence of psoriasis still useful tools to identify homogeneous disease entities in juvenile idiopathic arthritis? J. Rheumatol. 30, 1900–1903 (2003).

  3. 3.

    et al. Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis Rheum. 63, 267–275 (2011).

  4. 4.

    et al. Biologic similarities based on age at onset in oligoarticular and polyarticular subtypes of juvenile idiopathic arthritis. Arthritis Rheum. 62, 3249–3258 (2010).

  5. 5.

    & Pediatric regulatory initiatives. Handb. Exp. Pharmacol. 205, 245–268 (2011).

  6. 6.

    et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. (Hoboken) 63, 465–482 (2011).

  7. 7.

    Pediatric rheumatology: strengths and challenges of a new guide for treating JIA. Nat. Rev. Rheumatol. 7, 377–378 (2011).

  8. 8.

    & Paediatric rheumatology—a global perspective. Best Pract. Res. Clin. Rheumatol. 20, 201–221 (2006).

  9. 9.

    , & A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford) 49, 91–98 (2010).

  10. 10.

    et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann. Rheum. Dis. 70, 1605–1612 (2011).

Download references

Author information


  1. University of Genoa, Pediatria II e Reumatologia, Istituto G. Gaslini, Largo G. Gaslini 5, 16147 Genoa, Italy.

    • Alberto Martini


  1. Search for Alberto Martini in:

Competing interests

The author declares no competing financial interests.

About this article

Publication history



Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing